Skip to main navigation

The link is opening in a new window or tab that may or may not accessible Opens an external site Opens an external site in a new window

Pre-Header Contact

800-449-3353 | custserv@rockwellmed.com |

Footer Socials

Pre-Header Menu

Careers | Contact Us

Client Header Links

Home
Our Company
Our Therapeutic Focus
Our Technology
Hemodialysis Concentrates
Investors

Investor Relations

Press Releases

Main navigation

Investor Home
Press Releases
Events & Presentations
Corporate Governance
Management
Annual Meeting
Financial Information
Stock Information
Investor FAQs
Contact Us
Shareholder Tools

Press Releases

Year

May 16, 2022

Rockwell Medical Provides First Quarter 2022 Financial and Operational Update

PDF Version

May 12, 2022

Rockwell Medical Submits Supplemental Data to FDA for IND Application for Phase 2 FPC Home Infusion Trial

PDF Version

May 12, 2022

Rockwell Medical Announces 1-for-11 Reverse Stock Split

PDF Version

May 11, 2022

Rockwell Medical, Inc. to Report First Quarter 2022 Financial and Operating Results on May 16, 2022

PDF Version

Apr 25, 2022

Rockwell Medical Announces Completion of Patient Enrollment Ahead of Schedule in Pivotal Phase 3 Clinical Trial of Triferic® in China

PDF Version

Apr 20, 2022

Rockwell Medical to Present at Noblecon18 Investor Conference

PDF Version

Apr 11, 2022

Rockwell Medical Expands Partnership with DaVita

PDF Version

Mar 15, 2022

New Survey from Rockwell Medical Reveals Management of Iron Deficiency Anemia in Home Infusion Patients Does Not Adequately Address Medical Need

PDF Version

Mar 09, 2022

Rockwell Medical Announces Upcoming Poster Presentation at the National Home Infusion Association’s 2022 Annual Conference

PDF Version

Feb 15, 2022

Rockwell Medical, Inc. to Present at Aegis Virtual Conference

PDF Version

Pagination

Current page 1
Page 2
Next page
Last page

Shareholder Tools

Snapshot

Email Alerts

RSS News Feeds

Have any questions?

Phone 248 432-1997

invest@rockwellmed.com

Client Header Links

Home
Our Company
Our Therapeutic Focus
Our Technology
Hemodialysis Concentrates
Investors
Contact

Footer Socials